Welcome to our dedicated page for Cybin SEC filings (Ticker: CYBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cybin Inc. filings document the U.S. disclosure record for its Helus Pharma clinical-stage pharmaceutical business. Form 6-K reports furnished by the Canadian issuer attach company news releases and, when specified, incorporate exhibits by reference into Form F-10 shelf registration materials.
The filings cover the company’s novel serotonergic agonist pipeline, including HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder, as well as clinical-research collaborations, regulatory-policy statements, scientific advisory board changes, management appointments, chief executive transition disclosures, listing and operating-name updates, and capital-structure matters related to shelf and equity distribution activity.
Cybin Inc., operating commercially as Helus Pharma, reports that Nature Medicine has published results from a Phase 2a randomized, placebo-controlled trial of SPL026 in adults with moderate-to-severe major depressive disorder. The single 21.5 mg intravenous dose met the primary endpoint, delivering statistically and clinically meaningful reductions in Montgomery-Åsberg Depression Rating Scale scores at two weeks versus placebo (mean difference: -7.35). Antidepressant effects appeared within one week, were sustained to three months, and some participants improved for up to six months, with no treatment-related serious adverse events reported. Response rates at Week 2 were 35% for SPL026 versus 12% for placebo, and remission rates were 29% versus 12%. Although intravenous SPL026 is not being advanced, the data support Helus’s short-acting serotonergic agonist approach and inform its HLP004 program, with Phase 2 topline data in generalized anxiety disorder expected in Q1 2026.
Tang Capital Management and related entities have exited their stake in Cybin Inc. In Amendment No. 3 to a Schedule 13G, Tang Capital Management, Kevin Tang, and affiliated partnerships and corporations report beneficial ownership of 0 shares of Cybin common stock, or 0% of the class, as of December 31, 2025.
The filing confirms they no longer have sole or shared voting or dispositive power over any Cybin shares and state that the securities were not acquired or held to change or influence control of the company.
Deep Track Capital and affiliated entities report owning 2,391,505 Cybin Inc. common shares, representing 4.74% of the class as of December 31, 2025. The position includes 537,250 warrants exercisable into common stock, subject to a 9.99% maximum beneficial ownership limitation.
The ownership calculation uses 50,431,381 shares, based on 49,894,131 common shares outstanding as of December 19, 2025 plus the warrants counted up to the stated cap. The filers certify the holdings are not for the purpose of changing or influencing control of Cybin.
Helus Pharma, formerly Cybin Inc., reported a larger loss but a much stronger balance sheet for the three and nine months ended December 31, 2025. The company, a clinical-stage pharmaceutical developer of novel serotonergic agonists, posted a nine‑month net loss of $101,003 compared with $60,300 a year earlier, driven mainly by higher research spending of $57,702 and general and administrative costs of $31,419.
Despite the wider loss, liquidity improved significantly. Cash increased to $195,128 from $93,922 as of March 31, 2025, supported by net financing inflows of $198,408, including a registered direct offering of 22,277,750 common shares and 4,605,500 pre‑funded warrants with gross proceeds of about $175,010, and an earlier at‑the‑market program raising $10,465. Total assets rose to $290,112 and shareholders’ equity to $273,934, while the accumulated deficit reached $342,540.
The company issued and then fully extinguished $50,000 of unsecured convertible debentures during the period, recognizing a fair value loss of $5,500 before repaying the remaining principal and fees. It also expanded equity‑based incentives, with 4,169,617 stock options, 12,205,335 warrants, 4,605,500 pre‑funded warrants and 4,164,440 restricted share units outstanding at December 31, 2025. Helus Pharma subsequently moved its U.S. listing to Nasdaq under the symbol “HELP” and notes clinical and commercial commitments, including up to $109,950 for contracted studies and milestone obligations of up to $9,500 under a license agreement, alongside ongoing development of its HLP003, HLP004 and HLP005 programs.
Cybin Inc.’s commercial operating unit Helus Pharma has appointed industry veteran Michael Cola as Chief Executive Officer, effective immediately. He brings more than 30 years of experience in neuroscience, rare disease and specialty pharmaceuticals, including leading Shire’s Specialty Pharmaceutical business and senior roles at Astra-Merck and AstraZeneca.
Helus is advancing a pipeline of novel serotonergic agonists for serious mental health disorders, with Phase 2 data for HLP004 expected in the first quarter of 2026 and Phase 3 topline data for HLP003 expected in the fourth quarter of 2026. The company has filed more than 350 patent applications globally and has been granted over 100 patents as it moves from early clinical development toward later-stage execution, global regulatory engagement and long-term commercial planning.
Cybin Inc. has filed a Form 25 to remove its common shares from listing and/or registration on the NYSE American under Section 12(b) of the Securities Exchange Act of 1934. The company states that it has reasonable grounds to believe it meets all requirements for this filing and that the notification has been signed by its Chief Financial Officer, Greg Cavers. This filing starts the formal process for Cybin’s common shares to cease being listed and/or registered on the NYSE American, in accordance with exchange and SEC rules.
Cybin Inc. filed a Form 6-K as a foreign private issuer for December 2025. The filing states that Exhibit 99.1 from this report is incorporated by reference into Cybin’s existing Form F-10 registration statement, allowing that exhibit to become part of the company’s Canadian shelf-style offering document.
Cybin Inc. filed a Form 6-K as a foreign private issuer for December 2025. The report primarily updates investors on corporate documents rather than financial results. Cybin states that Exhibits 99.1 and 99.2 to this Form 6-K are incorporated by reference into its existing Form F-10 shelf registration statement. The exhibit index shows an Equity Distribution Agreement dated December 30, 2025, a consent from Aird & Berlis LLP, and a press release dated December 30, 2025, indicating the company is formalizing distribution arrangements and related legal consents within its Canadian shelf registration framework.